We are a global medical company developing Digital Therapeutics (DTx) for oncology. Our clinically-validated, self-care mobile application Living Well supports cancer patients' behavioural and mental health needs to improve their quality of life and overall outcomes. Our solutions increase the effectiveness of treatment, provide essential data for pharma & providers, and generate savings for healthcare systems. We aim to become the global leader in Digital Therapeutics for oncology, providing cancer patients with comprehensive solutions that are fully tailored to their medical conditions. We strive to create a portfolio of medical software products that combine world-leading expertise in medicine and technology and cover cancer patients' entire behavioural support needs and make a patient’s life better. Prosoma Digital Therapeutics is developed by medical experts and patients. We partner with the most renowned organisations for clinical trials and large-scale commercial partners in the USA and Germany. We are a part of various acceleration programmes such as Accelerate Cambridge, Incredibles, and the HealthHub at the University of California. Prosoma meet EU Medical Device Regulations: ISO 13485, ISO 62304, and ISO 27001.